OSIVAX

​Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology, oligoDOM®, which is designed to induce powerful CD8 T-cell responses. Osivax' mission is to revolutionize influenza prevention with a universal flu vaccine covering both current and future influenza infections by leveraging its unique oligoDOM® technology platform.​

Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, to accelerate the development of the oligoDOM® technology platform, which capitalizes on: 

• Over 12 years of R&D on a breakthrough approach to induce CD8 T-cell immunity
•  A solid preclinical package developed by OSIVAX for its influenza vaccine candidate
•  Clinical and preclinical data generated by leading independent teams in Europe
• (Oxford University, DKFZ / Heidelberg University, Inserm / CNRS...)​​​

Osivax relies on an international leadership team with complementary life science experiences and a prestigious international Scientific and Clinical Advisory Board with industry and academic expertise.

Osivax is based in Lyon (France) and Liège (Belgium), two leading clusters of vaccine R&D in Europe. 

Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens.